Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial ...
(PR-inside.com) LUND, SE / ACCESS Newswire / June 8, 2026 / Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed by Shanghai Henlius Biotech, Inc. According to communication shared by Henlius, the first patients have n…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


